Colorectal Cancer

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Liver surgery for colorectal cancer hepatic metastases has, for the most part, a minimal and brief negative impact on patient-reported outcomes.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Patients are less likely to complete colorectal cancer screening if their physician recommended colonoscopy rather than recommending fecal occult blood testing.

Universal tumor testing and a detailed personal and family history assessment are recommended for all patients with newly diagnosed colorectal cancer.

Adding brivanib alaninate to cetuximab had no survival advantage over cetuximab alone in patients with KRAS wild-type chemorefractory metastatic colorectal cancer.

New research on predictive and prognostic biomarkers for therapy targeting EGFR strongly suggests that panitumumab should be reserved for mCRC tumors with wild-type KRAS.

Adding oxaliplatin to conventional chemotherapy increases survival in patients with advanced colon cancer in a broad range of community practice settings.

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

Patients who are obese before being diagnosed with colorectal cancer are more likely to die of their disease than patients who are at a normal weight prediagnosis.

New findings suggest that increased serum glucose levels may be a risk factor for colorectal cancer in postmenopausal women.

Higher cancer fatalism, a term that refers to the belief that a cancer diagnosis leads inevitably to death, may be associated with a lower rate of colorectal cancer screening.

Men with colorectal cancer are not routinely informed about the potential for erectile dysfunction or how the condition can best be managed.

Medicare beneficiaries with CRC who made a higher number of visits to their PCP before their diagnosis had lower disease-related mortality and lower all-cause mortality.

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

The presence or absence of lymph node involvement has long been recognized as a critically relevant prognostic factor in solid tumor oncology.

Dr. Emily Chan from Vanderbilt-Ingram Cancer Center Discusses the Adjuvant Colorectal NO147 Trial

Dr. Axel Grothey from the Mayo Clinic Discusses Novel Agents for Colorectal Cancer

Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.

Investigators are recommending that black women follow a 'prudent dietary pattern' in lieu of a more Western-style diet to prevent the development of colorectal adenomas.

A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.

A late phase metastatic colorectal cancer trial was stopped after demonstrating a statistically significant improvement in OS.

Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.